NO20001601L - Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser - Google Patents

Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser

Info

Publication number
NO20001601L
NO20001601L NO20001601A NO20001601A NO20001601L NO 20001601 L NO20001601 L NO 20001601L NO 20001601 A NO20001601 A NO 20001601A NO 20001601 A NO20001601 A NO 20001601A NO 20001601 L NO20001601 L NO 20001601L
Authority
NO
Norway
Prior art keywords
apoa
agonists
apolipoprotein
native
inject
Prior art date
Application number
NO20001601A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001601D0 (no
Inventor
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Original Assignee
Dasseux Jean Louis
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dasseux Jean Louis, Renate Sekul, Klaus Buttner, Isabelle Cornut, Gunther Metz, Jean Dufourcq filed Critical Dasseux Jean Louis
Publication of NO20001601D0 publication Critical patent/NO20001601D0/no
Publication of NO20001601L publication Critical patent/NO20001601L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20001601A 1997-09-29 2000-03-28 Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser NO20001601L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020329 WO1999016409A2 (fr) 1997-09-29 1998-09-28 Methodes de therapie genique servant a produire des agonistes d'apolipoproteine a-i et leur utilisation pour traiter des troubles de la dyslipidemie

Publications (2)

Publication Number Publication Date
NO20001601D0 NO20001601D0 (no) 2000-03-28
NO20001601L true NO20001601L (no) 2000-05-26

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001601A NO20001601L (no) 1997-09-29 2000-03-28 Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser

Country Status (17)

Country Link
US (4) US6518412B1 (fr)
EP (1) EP1039934B1 (fr)
JP (1) JP2003525565A (fr)
KR (1) KR100650975B1 (fr)
CN (1) CN100345588C (fr)
AT (1) ATE323510T1 (fr)
AU (1) AU758307B2 (fr)
CA (1) CA2304814A1 (fr)
DE (1) DE69834267T2 (fr)
ES (1) ES2263221T3 (fr)
HU (1) HU225821B1 (fr)
IL (1) IL135324A0 (fr)
NO (1) NO20001601L (fr)
NZ (1) NZ503720A (fr)
PL (1) PL193662B1 (fr)
RU (1) RU2222545C2 (fr)
WO (1) WO1999016409A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
WO2001068852A2 (fr) * 2000-03-13 2001-09-20 Amgen Inc. Regulation apo-a-i de la signalisations des lymphocytes t
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
JP2007517550A (ja) 2004-01-02 2007-07-05 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド 高比重リポ蛋白をコーティングした医療デバイス
EP1799242A4 (fr) * 2004-09-16 2009-11-11 Univ California Peptides de type g et autres agents permettant d'ameliorer l'atherosclerose et d'autres pathologies
CA2584048C (fr) 2004-10-15 2016-08-09 Alan T. Remaley Peptides helicoidaux amphipathiques a plusieurs domaines et leurs methodes d'utilisation
AU2005314043A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN101489577B (zh) * 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 治疗心瓣膜病的方法和化合物
WO2007149355A2 (fr) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Nouveaux peptides qui favorisent un écoulement de lipides
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
CA2660743C (fr) * 2006-08-17 2015-11-24 The Uab Research Foundation Polypeptides immunogeniques de pcpa et leurs utilisations
WO2008039843A2 (fr) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Nouveaux peptides promouvant l'ecoulement lipidique
CA2697957A1 (fr) 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides synthetiques analogues d'apolipoproteine e et procedes d'utilisation
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (fr) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides favorisant l’efflux de lipides via abca1 et activant une lipoprotéine lipase
MX343654B (es) 2009-02-16 2016-11-16 Cerenis Therapeutics Holding Sa Peptidos mimeticos de la apolipoproteina a-i.
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
RU2013112562A (ru) * 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Тетранектин-аполипопротеин а-i, содержащие его липидные частицы и его применение
DK2673296T3 (en) * 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
WO2012162392A1 (fr) 2011-05-23 2012-11-29 Timothy Hla Matériaux protecteurs de l'endothélium et procédés d'utilisation
MX2014001920A (es) 2011-08-25 2014-04-14 Hoffmann La Roche Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
CA2947127A1 (fr) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Marqueurs de therapie hdl
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US12257352B2 (en) * 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用
WO2025128566A1 (fr) * 2023-12-13 2025-06-19 University Of Kentucky Research Foundation Lipoprotéine synthétique haute densité et procédé de traitement de la septicémie et d'états associés

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (fr) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (fr) 1979-06-22 1984-08-28 Jurg Schrank Produits pharmaceutiques
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
ATE171192T1 (de) 1992-06-12 1998-10-15 Innogenetics Nv Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
WO1995027512A2 (fr) * 1994-04-11 1995-10-19 Baylor College Of Medicine Compositions et procedes de therapie genique pour traiter des maladies
RU2043116C1 (ru) * 1994-05-04 1995-09-10 Александр Иванович Арчаков Пептид апов-рецептора, ответственный за связывание липопротеинов низкой плотности
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
WO1997009048A1 (fr) * 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Utilisation d'une thienotriazolodiazepine pour augmenter les concentrations de l'apolipoproteine a-i
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
AU9671498A (en) 1999-04-23
HUP0003924A3 (en) 2005-12-28
AU758307B2 (en) 2003-03-20
CA2304814A1 (fr) 1999-04-08
US6844327B2 (en) 2005-01-18
RU2222545C2 (ru) 2004-01-27
DE69834267T2 (de) 2007-01-04
KR20010030806A (ko) 2001-04-16
NZ503720A (en) 2002-10-25
IL135324A0 (en) 2001-05-20
ES2263221T3 (es) 2006-12-01
EP1039934B1 (fr) 2006-04-19
CN1303298A (zh) 2001-07-11
PL193662B1 (pl) 2007-03-30
EP1039934A4 (fr) 2002-11-27
JP2003525565A (ja) 2003-09-02
PL358529A1 (en) 2004-08-09
US6518412B1 (en) 2003-02-11
US20030208059A1 (en) 2003-11-06
WO1999016409A2 (fr) 1999-04-08
HUP0003924A2 (hu) 2001-01-29
US7250407B2 (en) 2007-07-31
ATE323510T1 (de) 2006-05-15
US20050148513A1 (en) 2005-07-07
CN100345588C (zh) 2007-10-31
US20080050351A1 (en) 2008-02-28
EP1039934A1 (fr) 2000-10-04
KR100650975B1 (ko) 2006-11-29
DE69834267D1 (de) 2006-05-24
NO20001601D0 (no) 2000-03-28
HU225821B1 (en) 2007-10-29

Similar Documents

Publication Publication Date Title
NO20001601L (no) Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
BG101115A (bg) Манипулиране на протопорфириноген оксидазната ензимна активност в еукариотични организми
BR9810248A (pt) Sequências reguladoras para plantas transgênicas.
ATE89006T1 (de) Expression von menschlichem proapolipoprotein a- 1.
WO1999053040A3 (fr) Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne
DK1472344T3 (da) Bakteriofaglysin
Nelson et al. Molecular cloning of cDNA encoding the C subunit of H (+)-ATPase from bovine chromaffin granules
DE60235297D1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker-gen und therapeutische anwendungen davon
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
BR0209551A (pt) Promotor de gene especìfico de folha de café
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
WO1999046374A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
DK1222294T3 (da) Promotor til regulering af ekspression af fremmede gener
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO1999046375A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
PL1711612T3 (pl) Kasety ekspresyjne do dwukierunkowej ekspresji transgenicznej kwasów nukleinowych w roślinach
BR9910703A (pt) Processo para produzir uma cepa thy a- do vibrio cholerae, cepa thy a- do vibrio cholerae, sequências de nucleotìdeo de um gene thy a do vibrio cholerae e de uma região de flanque 5' e 3' de um gene estrutural gene thy a do vibrio cholerae, proteìna, e, vacina
WO1999042137A3 (fr) Regulation de genes therapeutiques par un promoteur de stress en therapie genique, et compositions et procedes associes
ATE226446T1 (de) Muteine von wildtyp-cytokinen und ihre verwendung als immunogene
DE60319333D1 (de) Hitzelabile Desoxyribonuklease I-Varianten
Sgambati et al. Cytotoxic activity of chimeric protein PD-L4UWSCItr does not appear be affected by specificity of inhibition mediated by anti-protease WSCI domain
CN104177487A (zh) 一种利用原核表达系统制备神经生长抑制因子重组蛋白的方法